do glp 1 drugs cause blindness Risk Vision loss risks in patients

The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)

4.1 Increased BAX/Bcl-X L ratio, BAD, phosphorylated ERK, mitochondrial dysfunction and cellular stress in human epileptic brain tissues linked to CYP-mediated drug interactions We identified that patients taking a combination of multiple ASMs with varying CYP involvementNON-CYP + CYP substrate, NON-CYP + CYP inducer, CYP substrate + CYP substrate and CYP substrate + CYP inducershowed differential effects on the ratio of pro-apoptotic (e.g., BAX) and anti-apoptotic (e.g., Bcl-X L ) proteins in the epileptic brain tissues

Taking B12 supplements with meals, adjusting doses, or switching formulations can significantly reduce stomach discomfort

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine

The most common side effect is irritation at the site of injection which could last up to 5-10 minutes

12 was the first to use in vivo T2-mapping in order to quantify water content of the IVD 4 in the lumbar spine before and after exercise